Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) – Market Access and Reimbursement Insights Report – 2025

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market Access and Reimbursement Insights

Thelansis’s “Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Overview

Chronic rhinosinusitis without nasal polyposis (CRSsNP) manifests as the persistence of at least two out of four key symptoms over a period of 12 weeks or more: nasal obstruction, anterior or posterior nasal discharge, reduction or loss of smell, and facial pain/pressure/fullness. Additional symptoms may include rhinorrhea and facial discomfort. Conditions predisposing individuals to CRSsNP comprise acute rhinosinusitis, often triggered by viral respiratory infections, as well as allergic and non-allergic rhinitis, asthma, bronchitis, pneumonia, gastroesophageal reflux disease, adenotonsillitis, sleep apnea, and otitis media. Moreover, the likelihood of allergic conjunctivitis, atopic dermatitis, asthma, urinary tract infections, and skin/soft tissue infections increases with a diagnosis of CRSsNP.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) – Market Access and Reimbursement Insights Report – 2025